Shots:

• The US FDA has granted FT designation to the development of ASP1128 for patients at increased risk of developing moderate to severe acute kidney injury (AKI) after coronary artery bypass and/or valve (CABG/V) surgery
• In 2018- Astellas acquired Mitobridge to focus on developing mitochondrial-directed therapies and recognizes the serious burden of AKI on patients. The development of its lead candidate- ASP1128 will robust Astellas’ mitochondrial dysfunction pipeline
• ASP1128 is a selective modulator of PPARδ intended to have protective effects on kidney cells that under cellular stress following CABG/V surgery by promoting fatty acid oxidation in the mitochondria

Click here to­ read full press release/ article 

Ref: Astellas | Image: Astellas